Current Hypertension Reports

, Volume 10, Issue 5, pp 343–344 | Cite as

Telmisartan, ramipril, or both in patients at high risk for vascular events

  • Donald G. Vidt
Clinical Trials Report


  1. 1.
    Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153. [Errata, N Engl J Med 2000, 342:784, 1376.]CrossRefGoogle Scholar
  2. 2.
    Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. [Erratum, N Engl J Med 2004, 350:203.]PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Donald G. Vidt

There are no affiliations available

Personalised recommendations